+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease



Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease



Journal of Pediatric Hematology/Oncology 19(4): 313-318



To observe the safety and efficacy of hydroxyurea (HU), a drug that stimulates fetal hemoglobin (Hb F) production, in previously severely ill children with sickle cell disease. HU was given in an uncontrolled study to 35 children with sickle cell disease, aged from 3 to 20 years, suffering from frequent painful crises. Mean duration of treatment was 32 months (range: 12-59 months). HU induced an increase in Hb F levels in all children out one; this increase was maximal after 9 months of treatment, was largely sustained thereafter, and was related to HU dose and inversely to patients' age. We also noted an apparent reduction in crisis, which occurred principally after 3 months of therapy and did not seem strictly correlated with the rise in Hb F level. No serious hematopoietic complication was observed. Growth curves and sexual development were not modified. Our data support the efficacy of HU in reducing painful events in children with sickle cell disease. Short- and middle-term tolerances are good. Thus, we think that HU can be given to children affected by frequent and severe painful crises. We recommend, however, very cautious use of this drug, because its long-term effects in children are still unknown.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047782658

Download citation: RISBibTeXText

PMID: 9256830


Related references

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood 91(12): 4472-4479, 1998

Hydroxyurea treatment in severely affected sickle cell disease children. Beuzard, Y, Lubin, B, Rosa, J, INSERM Colloquium; Sickle cell disease and thalassaemias: New trends in therapy, Colloque INSERM; Sickle cell disease and thalassaemias: New trends in therapy 171-172, 1995

Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. Archives of Disease in Childhood 81(5): 437-439, 1999

A pilot study of hydroxyurea treatment of severely affected children with sickle cell disease. Pediatric Research 33(4 PART 2): 147A, 1993

Sickle cell disease: a continuing clinical and research dilemma: Bone marrow transplantation for sickle cell disease Walters, M.C. et al. (1996) New Engl. J. Med. 335, 369376 Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial Ferster, A. et al. (1996) Blood 88, 19601961. Molecular Medicine Today 2(11): 450-451, 1996

Hydroxyurea therapy in children severely affected with sickle cell disease. Journal Of Pediatrics. 128(6): 820-828, 1996

Hydroxyurea therapy in severely affected children with sickle cell disease. Pediatric Research 35(4 PART 2): 163A, 1994

Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin 36(4): 323-332, 2012

Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?. Pediatric Blood and Cancer 63(5): 844-847, 2016

The safety and efficacy of hydroxyurea in 2 to 5 year old children with sickle cell disease. Pediatric Research 45(4 PART 2): 147A, 1999

Hydroxyurea is safe and effective in 2 to 5 year old children with sickle cell disease. Blood 94(10 SUPPL 1 PART 1): 417a, Nov 15, 1999

Screening of New Therapeutic Agents for the Treatment of Sickle Cell Disease Five-Year Summary of the NIH Sickle Cell Disease Reference Laboratory. Blood 100(11): Abstract No 3564, November 16, 2002

Cyclic therapy with hydroxyurea in preventing painful crises of sickle cell disease A five year follow up study. Blood 88(10 SUPPL 1 PART 1-2): 21B, 1996

A two-year pilot trial of hydroxyurea in very young children with sickle cell disease. Blood 94(10 SUPPL 1 PART 1): 644a, Nov 15, 1999

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatric Hematology and Oncology 16(3): 221-232, 1999